The potential corona vaccine from AstraZeneca and the University of Oxford appears to be 70 percent protected, reports the pharmacist Monday.
What is striking about the study results is that the effectiveness of the vaccine increased in a group of volunteers who first received half a dose, followed by a full dose. For them, the vaccine seemed to protect as much as 90 percent.
The vaccine study involved 20,000 volunteers, half in the UK, the other half in Brazil. Thirty (non-serious) corona cases have been identified in people who received two full doses of the vaccine. 101 cases were identified in the control group, who received a placebo.
The potential vaccine from AstraZeneca is seen by the WHO health organization as the most promising. The European Commission has already signed a deal with AstraZeneca and hopes to receive 300 million doses if the vaccine is approved.
Minister Hugo de Jonge of Public Health wrote in a Friday brief to the House of Representatives that the vaccine from AstraZeneca, together with that from Pfizer, currently seems the most promising for rapid availability. AstraZeneca expressed its hope earlier this month to distribute the first vaccines in early 2021.
In recent weeks, vaccines from pharmaceuticals Pfizer and Moderna were found to protect 90 percent.